The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|October 2, 2001
- Pharmaceutical Technology-10-02-2001
- Volume 25
- Issue 10
Entering into an Alliance with Big Pharma: Benchmarks for Drug Delivery Contract Service Providers
Author(s)Anton Gueth
The author proposes a strategy for achieving a successful partnership with Big Pharma on the basis of forming a relationship with the company, deliberately managing the alliance, and clearly defining roles and responsibilities.
Advertisement
Articles in this issue
about 25 years ago
Outsourcing Outlookabout 25 years ago
Hydrogels for the Controlled Release of Pharmaceutical Proteinsabout 25 years ago
Near-Infrared Inspection Complements Other QC Systemsabout 25 years ago
Safety and Manufacturing Standardsabout 25 years ago
Current Status of the Oral Delivery of Insulinabout 25 years ago
Laboratory Equipment Qualificationabout 25 years ago
Filter Integrity Testing in Liquid Applications, Revisited, Part IAdvertisement
Related to this article
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement